Establishment of a pathomic-based machine learning model to predict CD276 (B7-H3) expression in colon cancer

被引:1
|
作者
Li, Jia [1 ]
Wang, Dongxu [1 ]
Zhang, Chenxin [2 ]
机构
[1] 983rd Hosp Joint Logist Support Force PLA, Dept Gastroenterol, Tianjin, Peoples R China
[2] 983rd Hosp Joint Logist Support Force PLA, Dept Gen Surg, Tianjin, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2024年 / 13卷
关键词
CD276; pathomics; prognostic biomarkers; colon cancer; machine learning; histopathological images; IMMUNE CHECKPOINT; PD-L1; EXPRESSION; GENE SIGNATURE; PROGNOSIS; VALIDATION; CARCINOMA; NIVOLUMAB;
D O I
10.3389/fonc.2023.1232192
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CD276 is a promising prognostic indicator and an attractive therapeutic target in various malignancies. However, current methods for CD276 detection are time-consuming and expensive, limiting extensive studies and applications of CD276. We aimed to develop a pathomic model for CD276 prediction from H&E-stained pathological images, and explore the underlying mechanism of the pathomic features by associating the pathomic model with transcription profiles. A dataset of colon adenocarcinoma (COAD) patients was retrieved from the Cancer Genome Atlas (TCGA) database. The dataset was divided into the training and validation sets according to the ratio of 8:2 by a stratified sampling method. Using the gradient boosting machine (GBM) algorithm, we established a pathomic model to predict CD276 expression in COAD. Univariate and multivariate Cox regression analyses were conducted to assess the predictive performance of the pathomic model for overall survival in COAD. Gene Set Enrichment Analysis (GESA) was performed to explore the underlying biological mechanisms of the pathomic model. The pathomic model formed by three pathomic features for CD276 prediction showed an area under the curve (AUC) of 0.833 (95%CI: 0.784-0.882) in the training set and 0.758 (95%CI: 0.637-0.878) in the validation set, respectively. The calibration curves and Hosmer-Lemeshow goodness of fit test showed that the prediction probability of high/low expression of CD276 was in favorable agreement with the real situation in both the training and validation sets (P=0.176 and 0.255, respectively). The DCA curves suggested that the pathomic model acquired high clinical benefit. All the subjects were categorized into high pathomic score (PS) (PS-H) and low PS (PS-L) groups according to the cutoff value of PS. Univariate and multivariate Cox regression analysis indicated that PS was a risk factor for overall survival in COAD. Furthermore, through GESA analysis, we found several immune and inflammatory-related pathways and genes were associated with the pathomic model. We constructed a pathomics-based machine learning model for CD276 prediction directly from H&E-stained images in COAD. Through integrated analysis of the pathomic model and transcriptomics, the interpretability of the pathomic model provide a theoretical basis for further hypothesis and experimental research.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer
    Inamura, Kentaro
    Takazawa, Yutaka
    Inoue, Yosuke
    Yokouchi, Yusuke
    Kobayashi, Maki
    Saiura, Akio
    Shibutani, Tomoko
    Ishikawa, Yuichi
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (07)
  • [2] B7-H3/CD276: An Emerging Cancer Immunotherapy
    Zhou, Wu-Tong
    Jin, Wei-Lin
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [3] Tumor B7-H3 (CD276) expression and survival of patients with pancreatic cancer
    Inamura, Kentaro
    Yokouchi, Yusuke
    Kobayashi, Maki
    Inoue, Yosuke
    Saiura, Akio
    Takazawa, Yutaka
    Ishikawa, Yuichi
    CANCER RESEARCH, 2018, 78 (13)
  • [4] Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma
    Liang, Jiayu
    Liu, Zhihong
    Pei, Tianjiao
    Xiao, Yingming
    Zhou, Liang
    Tang, Yongquan
    Zhou, Chuan
    Wu, Kan
    Zhang, Fuxun
    Zhang, Fan
    Yin, Xiaoxue
    Chen, Ni
    Wei, Xin
    Lu, Yiping
    Zhu, Yuchun
    DISEASE MARKERS, 2020, 2020
  • [5] Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
    Picarda, Elodie
    Ohaegbulam, Kim C.
    Zang, Xingxing
    CLINICAL CANCER RESEARCH, 2016, 22 (14) : 3425 - 3431
  • [6] Pan-cancer associations of B7-H3 (CD276) transcriptional expression across human malignancies
    Hwang, Justin
    Zorko, Nick
    Elliott, Andrew
    Lozada, Jose A.
    Radovich, Milan
    Heath, Elisabeth I.
    Agarwal, Neeraj
    McKay, Rana R.
    Garje, Rohan
    Bastos, Bruno R.
    Hoon, Dave S. B.
    Nabhan, Chadi
    Sledge, George W.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meninninma
    Deng, Jiaojiao
    Ma, Mengyin
    Wang, Daijun
    Zhu, Hongda
    Hua, Lingyang
    Sun, Shuchen
    Chen, Hong
    Cheng, Haixia
    Qian, Zhi Rong
    Xie, Qing
    Zhang, Tao
    Gong, Ye
    WORLD NEUROSURGERY, 2020, 135 : e12 - e18
  • [8] Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis
    Inamura, Kentaro
    Yokouchi, Yusuke
    Kobayashi, Maki
    Sakakibara, Rie
    Ninomiya, Hironori
    Subat, Sophia
    Nagano, Hiroko
    Nomura, Kimie
    Okumura, Sakae
    Shibutani, Tomoko
    Ishikawa, Yuichi
    LUNG CANCER, 2017, 103 : 44 - 51
  • [9] Expression of B7-H3 (CD276) in surgically resected esophageal squamous cell carcinoma.
    Maruki, Yuta
    Takashima, Atsuo
    Miyamoto, Takahiro
    Hirano, Hidekazu
    Shoji, Hirokazu
    Honma, Yoshitaka
    Iwasa, Satoru
    Okita, Natsuko
    Kato, Ken
    Sekine, Shigeki
    Koyanagi, Kazuo
    Daiko, Hiroyuki
    Kitano, Shigehisa
    Aoki, Kazunori
    Boku, Narikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [10] Expression and Prognostic Value of a Novel B7-H3 (CD276) Antibody in Acute Myeloid Leukemia
    Stefanczyk, Sylwia A.
    Hayn, Clara
    Heitmann, Jonas
    Jung, Susanne
    Zekri, Latifa
    Maerklin, Melanie
    CANCERS, 2024, 16 (13)